LBF20207PG28: Difference between revisions
No edit summary |
No edit summary |
(No difference)
|
Revision as of 10:00, 25 February 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR1711 |
LipidMaps | LMFA03010148 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20207PG28 |
5-trans Prostaglandin E2 | |
---|---|
Structural Information | |
9-oxo-11α,15S-dihydroxy-prosta-5E,13E-dien-1-oic acid | |
| |
Formula | C20H32O5 |
Exact Mass | 352.224974134 |
Average Mass | 352.46508 |
SMILES | C(CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)[C@@H](CC1=O)O)CC |
Physicochemical Information | |
5-trans PGE2 is naturally produced by some gorgonian corals and is also a common impurity in commercial lots of PGE1. | |
5-trans PGE2 has 18 times potency in activating adenylate cyclase compared to PGE2. Hensby_CN et al. 5-trans PGE2 accelerates fibrinolysis by enhancing plasminogen activation mediated dby tissue-type plasminogen activator. Shimokawa_M et al. And it also inhibits platelet | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|